Viral Clearance Market - Strategic Insights and Forecasts (2026-2031)

The viral clearance market is projected to expand at a CAGR of 10.4%, increasing from USD 917.9 million in 2026 to USD 1,505.3 million by 2031.

Viral clearance aims to prevent the contamination of the desired product by effectively eliminating viruses from the sample, either through complete removal or by rendering them non-infectious. The applications of viral clearance encompass various areas, including blood products, recombinant proteins, cellular and gene therapy products, vaccines, as well as other relevant fields. The significant growth drivers for the viral clearance industry include the emergence and growth of the pharmaceutical and biotech industry, as well as academic research institutes.

Viral Clearance Market Drivers:

• Rising pharmaceutical sector bolsters the viral clearance market growth.

Viral clearance is used in the pharmaceuticals industry to ensure the safety and efficiency of biopharmaceutical products, and as the industry experiences significant growth due to the increasing demand for biologics, coupled with the increased government investments and proactive initiatives, the need for viral clearance becomes more prominent. For instance, in March 2022, in India, the Strengthening of Pharmaceutical Industry (SPI) Scheme unveiled a financial outlay of Rs. 500 crores for the duration of FY 2021-22 to FY 2025-26. Such initiatives are expected to provide a positive outlook to the market demand for viral clearance, thereby augmenting the overall market growth.

• Emerging research and development drive the viral clearance market expansion.

Viral clearance is used in research and development (R&D) to ensure the safety and efficiency of biopharmaceutical products. The growing demand for innovative biologics and advancements in biotechnology is promoting R&D activities in the pharmaceutical industry. Moreover, due to an increase in R&D investments, the need for viral clearance techniques to address regulatory requirements and mitigate viral contamination risks rises. Roche, a renowned healthcare leader, significantly increased its investment in research and development (R&D) to $14.7 billion in 2022, marking a notable rise from $13.3 billion in the previous year.

• Technological advancements are driving viral clearance market growth.

The continuous progress in technological advancements of viral clearance techniques, including chromatography, filtration, and viral inactivation methods, has led to notable enhancements in the efficiency and effectiveness of viral clearance processes. As a result, these advancements play a pivotal role in driving the growth of the market, as they enable biopharmaceutical companies to ensure the safety and purity of their products through more efficient and reliable viral clearance procedures, meeting stringent regulatory requirements, and addressing growing concerns regarding viral contamination risks. For instance, in June 2022, Bio-Rad Laboratories, Inc., introduced EconoFit Low-Pressure Prepacked Chromatography Column Packs to aid protein purification workflow development and resin screening experiments.

Viral Clearance Market Restraints:

• High cost restrains the viral clearance market growth.

The viral clearance industry faces hindrances due to the high costs associated with specialized equipment, the need for skilled personnel, and the requirement for extensive testing. These expenses can create barriers for smaller companies with limited financial resources, impeding their ability to invest in viral clearance procedures. Consequently, market growth may be hindered as smaller companies struggle to meet the financial requirements for implementing effective viral clearance practices, limiting their participation in the market.

Viral Clearance Market Geographical Outlook:

• North America is anticipated to be the market leader.

The North American region will hold a significant share of the viral clearance market due to the region's robust pharmaceutical and biotech industry, characterized by major players, extensive research and development activities, and advanced infrastructure, which has contributed to the overall regional market growth. Furthermore, the region has witnessed substantial investments in the pharmaceutical and biotech industry, propelled by the increasing demand for biologics, stringent regulatory guidelines, and the need to ensure patient safety. For instance, in September 2022, the Department of Health and Human Services announced a $40 million investment to expand biomanufacturing's role in producing active pharmaceutical ingredients (APIs), antibiotics, and critical medication components, enhancing pandemic response capabilities in the United States.

Viral Clearance Market Company Products:

• ClearancePlus: Charles River Laboratories offers ClearancePlus, a comprehensive viral clearance study that incorporates risk-based assessments. This service includes a standard practice of utilizing large-volume plating for all product-relevant samples, thereby enhancing claims of log reduction value (LRV) and effectively demonstrating robust virus reduction. The inclusion of these practices ensures a thorough evaluation of viral clearance efficacy, providing clients with reliable data on the effectiveness of their viral reduction strategies.

• USP Viral Clearance and Test Methodologies: Nelson Labs offers USP Viral Clearance and Test Methodologies, which are designed for conducting quality control testing on a range of animal-derived raw materials and processing reagents used in the manufacturing of biological products. These test methodologies serve to evaluate the potential for introducing viral contaminants, ensuring the safety and integrity of the final products. By employing USP-recommended viral clearance methods, Nelson Labs assists in maintaining high-quality standards and mitigating the risks associated with viral contamination during the production process.

• MockV RVLP Kit (M230): The MockV RVLP Kit, developed by Cygnus, utilizes a BSL-1 compatible stock solution containing non-infectious Retrovirus-like Particles (RVLP) derived from CHO cell culture. This solution serves as a spiking agent for viral clearance testing, ensuring the accuracy and reliability of the testing process. The kit includes essential components such as RVLP stock solution, a 96-well plate for sample analysis, RNA extraction and qPCR reagents, and a meticulously controlled RNA standard, enabling precise and dependable quantification of RVLP.

Viral Clearance Market Development

• September 2026: Clean Cells launched GMP-compliant next-generation sequencing (NGS) viral safety testing for viral vectors and recombinant preparations, integrating sequencing and bioinformatics following its acquisition of Xegen.

• August 2026: Eurofins BioPharma Product Testing Italy reported promising co-spiking study results, demonstrating comparable viral inactivation kinetics for PPV and BVDV, potentially improving viral clearance study efficiency.

• March 2026: Minaris Advanced Testing highlighted its viral clearance testing services for biologics, vaccines, and AAV therapies, supporting viral safety assessments through scientifically designed studies and regulatory-ready documentation.

• March 2026: ViruSure launched a GMP-validated adventitious viral agent detection test using Oxford Nanopore sequencing, consolidating multiple assays to improve viral contaminant detection in biopharmaceutical manufacturing.

• January 2026: Minaris upgraded its Philadelphia viral clearance laboratory, expanding capacity to four client suites and targeting approximately 25% higher throughput through improved workflows and digital monitoring.

List of Top Viral Clearance Companies:

• Merck KGaA

• Texcell SA

• WuXi AppTec

• Sartorius AG

• Nelson Labs

Viral Clearance Market Scope: